Duloxetine inhibits breast cancer progression by suppressing AKT signaling and inducing Bax/Bcl-2-mediated apoptosis.

Saved in:
Bibliographic Details
Title: Duloxetine inhibits breast cancer progression by suppressing AKT signaling and inducing Bax/Bcl-2-mediated apoptosis.
Authors: Wang J; Collaborative Innovation Center of Research and Development on the Whole Industry Chain for Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China., Yue Z; Collaborative Innovation Center of Research and Development on the Whole Industry Chain for Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China., Bu J; Collaborative Innovation Center of Research and Development on the Whole Industry Chain for Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China., Quan S; Collaborative Innovation Center of Research and Development on the Whole Industry Chain for Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China., Guo R; Collaborative Innovation Center of Research and Development on the Whole Industry Chain for Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China., Wang M; Collaborative Innovation Center of Research and Development on the Whole Industry Chain for Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.; College of Materia Medica, Henan University of Chinese Medicine, Zhengzhou, 450046, China., Shen J; Collaborative Innovation Center of Research and Development on the Whole Industry Chain for Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Shenjiduo@hactcm.edu.cn.; College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Shenjiduo@hactcm.edu.cn., Li M; Department of Oncology, Zhengzhou People's Hospital, Zhengzhou, 450003, China. Limin512_zz@126.com., Li Y; Collaborative Innovation Center of Research and Development on the Whole Industry Chain for Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Liyucheng@hactcm.edu.cn.; Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Liyucheng@hactcm.edu.cn.
Source: Medical oncology (Northwood, London, England) [Med Oncol] 2025 Jul 22; Vol. 42 (8), pp. 364. Date of Electronic Publication: 2025 Jul 22.
Publication Type: Journal Article
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1559-131X
DOI:10.1007/s12032-025-02919-7